Vimarsana
Biggest News Aggregation in the World

Page 3 - Actinium News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Actinium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Actinium Today - Breaking & Trending Today

Actinium (ACM) Trading 9.3% Lower Over Last Week - Vimarsana News

Actinium (ACM) Trading 9.3% Lower Over Last Week

Actinium (ACM) traded 0.6% higher against the dollar during the 24 hour period ending at 18:00 PM E.T. on April 1st. One Actinium coin can now be purchased for $0.0153 or 0.00000033 BTC on cryptocurrency exchanges. Actinium has a market capitalization of $616,037.82 and $8,762.00 worth of Actinium was traded on exchanges in the last […]

Actinium Market Capitalization Tops $640,951.75 (ACM) - Vimarsana News

Actinium Market Capitalization Tops $640,951.75 (ACM)

Actinium (ACM) traded 0.9% lower against the dollar during the 1-day period ending at 19:00 PM Eastern on March 30th. Over the last week, Actinium has traded 8.9% lower against the dollar. Actinium has a total market capitalization of $640,951.75 and approximately $13,154.00 worth of Actinium was traded on exchanges in the last day. One […]

Actinium Reports Encouraging Data From Phase 1 Portion Of Actimab-A, Venetoclax Combination Trial - Vimarsana News

Actinium Reports Encouraging Data From Phase 1 Portion Of Actimab-A, Venetoclax Combination Trial

WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) reported data from the phase 1 portion of its Actimab-A and venetoclax combination trial in patients with relapsed or refractory acute

Actinium Reports Positive Findings From Phase 1 Study Of Actimab-A - Vimarsana News

Actinium Reports Positive Findings From Phase 1 Study Of Actimab-A

WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) reported updated data from the recently complete Actimab-A and CLAG-M phase 1 combination trial for patients with relapsed or refractory

Hitachi, Tohoku University and Kyoto University Become World's First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal Radiation Therapy Called TAT - Vimarsana News

Hitachi, Tohoku University and Kyoto University Become World's First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal Radiation Therapy Called TAT

Helping to expedite the commercialization of a type of radiation therapy that is effective against cancer which has spread widely through bodyTOKYO, Oct 19, 2021 - (JCN Newswire) - Hitachi, Ltd. (TSE: